Pathophysiology, diagnosis and clinical management of hepatorenal syndrome: From classic to new drugs

Current Vascular Pharmacology

Volumn 12, Issue 1, 2014, Pages 125-135

  Barbano, Biagio ^a   Sardo, Liborio ^a   Gigante, Antonietta ^a   Gasperini, Maria Ludovica ^a   Liberatori, Marta ^a   Di Lazzaro Giraldi, Gianluca ^a   Lacanna, Antonio ^a   Amoroso, Antonio ^a   Cianci, Rosario ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Acute kidney injury; Hepatorenal syndrome; Refractory ascites; Terlipressin; Vaptans; Vasoconstrictors

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMINOGLYCOSIDE; CONIVAPTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LIXIVAPTAN; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; NORADRENALIN; POTASSIUM CHANNEL; PROSTACYCLIN; TERLIPRESSIN; VASOCONSTRICTOR AGENT; VASOPRESSIN;

ASCITES; BACTERIAL PERITONITIS; CARDIOMYOPATHY; CREATININE BLOOD LEVEL; HEART FUNCTION; HEMODYNAMIC PARAMETERS; HEPATORENAL SYNDROME; HUMAN; HYPONATREMIA; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY INJURY; LIVER CIRRHOSIS; PARACENTESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PORTAL HYPERTENSION; RENAL REPLACEMENT THERAPY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; VASOCONSTRICTION; VASODILATATION;

CREATININE; DIURETICS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEPATORENAL SYNDROME; HUMANS; HYPERTENSION, PORTAL; LIVER TRANSPLANTATION; PARACENTESIS; PORTASYSTEMIC SHUNT, TRANSJUGULAR INTRAHEPATIC; RECEPTORS, VASOPRESSIN; RENAL CIRCULATION; RENAL REPLACEMENT THERAPY; SPLANCHNIC CIRCULATION; SYMPATHETIC NERVOUS SYSTEM; VASOCONSTRICTOR AGENTS; VASODILATION;

EID: 84897398583     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/157016111201140327163930     Document Type: Review

References (125)

1. Ginès P, Angeli P, Lenz K, Møller S, et al. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. European Association for the Study of the Liver. J Hepatol 2010; 53: 397-417.
2. Fagundes C, Ginès P. Hepatorenal syndrome: a severe, but treatable, cause of kidney failure in cirrhosis. Am J Kidney Dis 2012; 59: 874-85.
3. Salerno F, Gerbes A, Ginès P, et al. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007; 56: 1310-8.
4. Jalan R. Acute-on-chronic liver failure: from concept to a new syndrome. Curr Opin Crit Care 2011; 17: 152.
5. Wadei HM. Hepatorenal syndrome: a critical update. Semin Respir Crit Care Med 2012; 33: 55-69.
6. Guevara M, Bru C, Ginès P, et al. Increased cerebral vascular resistance in cirrhotic patients with ascites. Hepatology 1998; 28: 39-44.
7. Arroyo V, Terra C, Ginès P. Advances in the pathogenesis and treatment of type-1 and type-2 hepatorenal syndrome. J Hepatol 2007; 46: 935-46.
8. Follo A, Llovet JM, Navasa M, et al. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology 1994; 20, 1495-501.
9. Toledo C, Salmerón JM, Rimola A, et al. Spontaneous bacterial peritonitis in cirrhosis: predictive factors of infection resolution and survival in patients treated with cefotaxime. Hepatology 1993; 17: 251-7.
10. Salerno F, Cazzaniga M, Merli M, et al. Diagnosis, treatment and survival of patientswith hepatorenal syndrome: a survey on daily medical practice. J Hepatol 2011; 55: 1241-8.
11. Alessandria C, Ozdogan O, Guevara M, et al. MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation. Hepatology 2005; 41: 1282-9.
12. Lieberman FL. Functional renal failure in cirrhosis. Gastroenterology 1970; 58: 108-10.
13. Rimola A, Gavaler J, Schade RR, et al. Effects of renal impairment on liver transplantation. Gastroenterology 1987; 93: 148-56.
14. Ginès P, Schrier RW. Renal failure in cirrhosis. N Engl J Med 2009; 361: 1279-90.
15. Schrier RW, Arroyo V, Bernardi M, et al. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988; 8: 1151-7.
16. Vallance P, Moncada S. Hyperdynamic circulation in cirrhosis: a role for nitric oxide? Lancet 1991; 337: 776-8.
17. Guarner C, Soriano G, Tomas A, et al. Increased serum nitrite and nitrate levels in patients with cirrhosis: relationship to endotoxemia. Hepatology 1993; 18: 1139-43.
18. Hecker M, Mülsch A, Bassenge E, et al. Vasoconstriction and increased flow: two principle mechanisms of shear stressdependent endothelial autacoid release. Am J Physiol 1993; 265: 828-33.
19. Bomzon A, Blendis LM. The nitric oxide hypothesis and the hyperdynamic circulation in cirrhosis. Hepatology 1994; 20: 1343-50.
20. Guarner F, Guarner C, Prieto J, et al. Increased synthesis of systemic prostacyclin in cirrhotic patients. Gastroenterology 1996; 90: 687-94.
21. Moore K, Ward P, Taylor G, et al. Systemic and renal production of thromboxane A2 and prostacyclin in decompensated liver disease and hepatorenal syndrome. Gastroenterology 1991; 100: 1069-77.
22. Moreau R, Komeichi H, Kirstetter P, et al. Altered control of vascular tone by adenosine triphosphate sensitive potassium channels in rats with cirrhosis. Gastroenterology 1994; 106: 1016-23.
23. Moreau R, Lebrec D. Endogenous factors involved in the control of arterial tone in cirrhosis. J Hepatol 1995; 22: 370-6.
24. Arroyo V, Ginès P, Gerbes A, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 1996; 23: 164-76.
25. Hampel H, Bynum GD, Zamora E, et al. Risk factors for the development of renal dysfunction in hospitalized patients with cirrhosis. Am J Gastroenterol 2001; 96: 2206-10.
26. Terg R, Gadano A, Cartier M, et al. Serum creatinine and bilirubin predict renal failure and mortality in patients with spontaneous bacterial peritonitis: a retrospective study. Liver Int 2009; 29: 415-9.
27. Bories PN, Campillo B, Azaou L, et al. Long-lasting NO overproduction in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 1997; 25: 1328-33.
28. Grangé JD, Amiot X. Nitric oxide and renal function in cirrhotic patients with ascites: from pathophysiology to practice. Eur J Gastroenterol Hepatol 2004; 16: 567-70.
29. Rodríguez-Ramos C, Galan F, Díaz F, et al. Expression of proinflammatory cytokines and their inhibitors during the course of spontaneous bacterial peritonitis. Dig Dis Sci 2001; 46: 1668-76.
30. Chin-Dusting JP, Rasaratnam B, Jennings GL, et al. Effect of fluoroquinolone on the enhanced nitric oxide-induced peripheral vasodilation seen in cirrhosis. Ann Intern Med. 1997; 127: 985-8.
31. Fernández J, Navasa M, Planas R, et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 2007; 133: 818-24.
32. Sugano, S. Endotoxin levels in cirrhotic rats with sterile and infected ascites. Gastroenterol Jpn 1992; 27: 348-53.
33. Fasolato S, Angeli P, Dallagnase L, et al. Renal failure and bacterial infections in pa-tients with cirrhosis: epidemiology and clinical features. Hepatology 2007; 45: 223-9.
34. Stein J. Regulation of the renal circulation. Kidney Int 1990; 38: 571-6.
35. Person PB, Ehmeke H, Naf B, et al. Sympathetic modulation of renal autoregulation by carotid occlusion in conscious dogs. Am J Physiol 1990; 258: 364-70.
36. thed. Philadelphia, PA: Lippincott Williams & Wilkins, 2007; pp 2179-205.
37. Badalamenti S, Graziani G, Salerno F, et al. Hepatorenal syndrome: new perspectives in pathogenesis and treatment. Arch Intern Med 1993; 153: 1957-67.
38. Laffi G, La Villa G, Pinzani M, et al. Arachidonic acid derivatives and renal function in liver cirrhosis. Semin Nephrol 1997; 17: 530-48.
39. Schneider AW, Kalk FJ, Klein CP. Effect of losartan, an angiotensin II receptor antagonist on portal pressure in cirrhosis. Hepatology 1999; 29: 334-9.
40. Garcia-Tsao G. Angiotensin II receptor antagonist in the pharmacological therapy: a caution. Gastroenterology 1999; 117: 740-2.
41. Epstein M, Weitzman RE, Preston S, et al. Relationship between plasma arginine vasopressin and renal water handling in decompensated cirrhosis. Miner Electrolyte Metab 1984; 10: 155-65.
42. Bichet D, Szatalawicz W, Chaimovitz C, et al. Role of vasopressin in abnormal water excretion in cirrhosis patients. Ann Intern Med 1982; 96: 413-7.
43. Zipser R, Hoefs J, Speckart P, et al. Prostaglandins: modulators of renal function and pressor resistance in chronic liver disease. J Clin Endocrinol Metab 1979; 48: 895-900.
44. Wong F. Hepatorenal syndrome. In: Lerma EV, Nissenson AR, Berns JS, Eds. Current Diagnosis and Treatment in Nephrology and Hypertension. McGraw Hill: New York 2009; pp 99-108.
45. Henriksen JH. Hepatorenal disorders: role of the sympathetic nervous system. Semin Liver Dis 1994; 14: 35-43.
46. Bichet DG, Van Putten VJ, Schrier RW. Potential role of increased sympathetic activity in impaired sodium and water excretion in cirrhosis. N Engl J Med 1982; 307: 1552-7.
47. Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 2004; 40: 55-64.
48. Wong F, Sniderman K, Liu P, et al. The effects of transjugular intrahepatic portasystemic shunt on systemic and renal hemodynamics and sodium homeostasis in cirrhotic patients with refractory ascites. Ann Intern Med 1995; 122: 816-22.
49. Lang F, Tschernko E, Schulze E, et al. Hepatorenal reflex regulating kidney function. Hepatology 1991; 14: 590-4.
50. Solis-Herruzo JA, Duran A, Favela V, et al. Effects of lumbar sympathetic block on kidney function in cirrhotic patients with hepatorenal syndrome. J Hepatol 1987; 5: 167-73.
51. Moller S, Henriksen JH. Cirrhotic cardiomyopathy: a pathophysiological review of circulatory dysfunction in liver disease. Heart 2002; 87: 9-15.
52. Ruiz-del-Arbol L, Urman J, Fernandez J, et al. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 2003; 38: 1210-8.
53. Wong F. Cirrhotic cardiomyopathy. Hepatol Int 2009; 3: 294-304.
54. Henriksen JH, Gøtze JP, Fuglsang S, et al. Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease. Gut 2003; 52: 1511-7.
55. Pateron D, Beyne P, Laperche T, et al. Elevated circulating cardiac troponin I in patients with cirrhosis. Hepatology 1999; 29: 640-3.
56. Henriksen JH, Bendtsen F, Hansen EF, et al. Acute non-selective beta-adrenergic blockade reduces prolonged frequency-adjusted QT interval (QTc) in patients with cirrhosis. J Hepatol 2004; 40: 239-46.
57. Pozzi M, Grassi G, Ratti L, et al. Cardiac, neuroadrenergic, and portal hemodynamic effects of prolonged aldosterone blockade in postviral child A cirrhosis. Am J Gastroenterol 2005; 100: 1110-6.
58. Meyers CM, Seeff LB, Stehman-Breen CO, et al. Hepatitis C and renal disease: an update. Am J Kidney Dis 2003; 42: 631-57.
59. nded. Malden, MA: Blackwell. 2005; pp 360-71.
60. Thabut D, Massard J, Gangloff A, et al. Model for end-stage liver disease score and systemic inflammatory response are major prognostic factors in patients with cirrhosis and acute functional renal failure. Hepatology 2007; 46: 1872-82.
61. Quinlan GJ, Martin GS, Evans TW. Albumin: biochemical properties and therapeutic potential. Hepatology 2005; 41: 1211-9.
62. Quinlan GJ, Mumby S, Martin GS, et al. Albumin influences total plasma antioxidant capacity favorably in patients with acute lung injury. Crit Care Med 2004; 32: 755-9.
63. Tandon P, Garcia-Tsao G. Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis 2008; 28: 26-42.
64. Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999; 341: 403-9.
65. Arroyo V, Fernandez J. Pathophysiological basis of albumin use in cirrhosis. Ann Hepatol 2011; 10: S6-14
66. Arroyo V, Fernández J. Management of hepatorenal syndrome in patients with cirrhosis. Nat Rev Nephrol 2011; 7: 517-26.
67. Cárdenas A, Ginès P, Uriz J, et al. Renal failure after upper gastrointestinal bleeding in cirrhosis: incidence, clinical course, predictive factors, and short-term prognosis. Hepatology 2001; 34: 671-6.
68. Akriviadis E, Botla R, Briggs W, et al. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a doubleblind, placebo-controlled trial. Gastroenterology 2000; 119: 1637-48.
69. Lebrec D, Thabut D, Oberti F, et al. Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis. Gastroenterology 2010; 138: 1755-62.
70. Clària J, Kent JD, Lopez-Parra M, et al. Effects of celecoxib and naproxen on renal function in nonazotemic patients with cirrhosis and ascites. Hepatology 2005; 41: 579-87.
71. Guevara M, Fernandez-Esparrach G, Alessandria C, et al. Effects of contrast media on renal function in patients with cirrhosis: a prospective study. Hepatology 2004; 40: 646-65.
72. Umgelter A, Reindl W, Wagner KS, et al. Effects of plasma expansion with albumin and paracentesis on hemodynamics and kidney function in critically ill cirrhotic patients with tense ascites and hepatorenal syndrome: a prospective uncontrolled trial. Crit Care 2008; 12: R4.
73. Moore KP, Wong F, Gines P, et al. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology 2003; 38: 258-66.
74. Dalfino L, Tullo L, Donadio I, et al. Intra-abdominal hypertension and acute renal failure in critically ill patients. Intensive Care Med 2008; 34: 707-13.
75. Arroyo V, Colmenero J. Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management. J Hepatol 2003; 38: 69-89.
76. Fernandez J, Monteagudo J, Bargallo X, et al. A randomized unblended pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis. Hepatology 2005; 42: 627-34.
77. Davenport A, Ahmad J, Al-Khafaji A, et al. Medical management of hepatorenal syndrome. Nephrol Dial Transplant 2012; 27: 34-41.
78. Marik PE, Baram M, Vahid B. Does central venous pressure predict fluid responsiveness? A systematic review of the literature and the tale of seven mares. Chest 2008; 134: 172-8.
79. Osman D, Ridel C, Ray P, et al. Cardiac filling pressures are not appropriate to predict hemodynamic response to volume challenge. Crit Care Med 2007; 35: 64-8.
80. Ruiz-del-Arbol L, Monescillo A, Arocena C, et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology 2005; 42: 439-47.
81. Hasper D, Jörres A. New insights into the management of hepatorenal syndrome. Liver Int 2011; 31 Suppl 3:27-30.
82. Uriz J, Ginès P, Cárdenas A, et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol 2000; 33: 43-8.
83. Nazar A, Pereira GH, Guevara M, et al. Predictors of response to therapy to terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 2010; 51: 219-26.
84. Gluud LL, Christensen K, Christensen E, et al. Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. Hepatology 2010; 51: 576-84.
85. Sharma P, Kumar A, Shrama BC, et al. An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response. Am J Gastroenterol 2008; 103: 1689-97.
86. Duvoux C, Zanditenas D, Hézode C, et al. Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study. Hepatology 2002; 36: 374-80.
87. Singh V, Dhungana SP, Singh B, et al. Midodrine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study. J Hepatol 2012; 56: 348-54.
88. Angeli P, Volpin R, Piovan D, et al. Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites. Hepatology 1998; 28: 937-43.
89. Angeli P, Volpin R, Gerunda G, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999; 29: 1690-7.
90. Skagen C, Einstein M, Lucey MR, et al. Combination treatment with octreotide, midodrine, and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome. J Clin Gastroenterol 2009; 43: 680-5
91. Gulberg V, Bilzer M, Gerbes AL. Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine. Hepatology 1999; 30: 870-5.
92. Lebrec D, Thabut D, Oberti F, et al. Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis. Gastroenterology 2010; 138: 1755-62.
93. Ali F, Raufi MA, Washington B, et al. Conivaptan: a dual vasopressin receptor v1a/v2 antagonist. Cardiovasc Drug Rev 2007; 25: 261-79.
94. Wong F, Watson H, Gerbes A, et al.; Satavaptan Investigators Group. Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity. Gut 2012; 61: 108-16.
95. Gines P, Wong F, Watson H, et al. Effects of satavaptan, a selective vasopressin V2 receptor antagonist, on ascites and serum sodium concentration in cirrhosis with hyponatremia. A randomized trial. Hepatology 2008; 48: 204-13.
96. Dahl E, Gluud LL, Kimer N, et al. Meta-analysis: the safety and efficacy of vaptans (tolvaptan, satavaptan and lixivaptan) in cirrhosis with ascites or hyponatraemia. Aliment Pharmacol Ther 2012; 36: 619-26.
97. Chan PS, Couplet J, Park HC, et al. VPA-985, A nonpeptide orally active and selective vasopressin V2 receptor antagonist. Adv Exp Med Biol 1998; 449: 439-43.
98. Guyader D, Patat A, Ellis-Grosse EJ, et al. Pharmacodynamic effects of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascites. Hepatology 2002; 36: 1197-205.
99. Wong F, Blei AT, Blendis LM, et al. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebocontrolled trial. Hepatology 2003; 37: 182-91.
100. Abraham WT, Shamshirsaz AA, McFann K, et al. Aquaretic effect of lixivaptan, an oral, nonpeptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients. J Am Coll Cardiol 2006; 47: 1615-21.
101. Abraham WT, Decaux G, Josiassen RC, et al. Oral lixivaptan effectively increases serum sodium concentrations in outpatients with euvolemic hyponatremia. Kidney Int 2012; 82: 1215-22.
102. FDA: Tolvaptan approval. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022275s 000_SumR.pdf
103. Gines P, Wong F, Watson H, et al. Clinical trial: short-term effects of combination of satavaptan, a selective vasopressin V2 receptor antagonist, and diuretics on ascites in patients with cirrhosis without hyponatraemia-a randomized, double-blind, placebo controlled study. Aliment Pharmacol Ther 2010; 31: 834-45.
104. Alessandria C, Ottobrelli A, Debernardi-Venon W, et al. Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study. J Hepatol 2007; 47: 499-505.
105. Ortega R, Ginès P, Uriz J, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 2002; 36: 941-8.
106. Martín-Llahí M, Pépin MN, Guevara M, et al; TAHRS Investigators. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology 2008; 134: 1352-9.
107. Rössle M, Gerbes AL. TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax: a critical update. Gut 2010; 59: 988-1000.
108. Boyer TD. Transjugular intrahepatic portosystemic shunts: current status. Gastroenterology 2003; 124:1700-10.
109. Brensing KA, Textor J, Perz J, et al. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in nontransplant cirrhotics with hepatorenal syndrome: a phase II study. Gut 2000; 47: 288-95
110. Testino G, Ferro C, Sumberaz A, et al. Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation. Hepatogastroenterology 2003; 50: 1753-5.
111. Guerrini GP, Pleguezuelo M, Maimone S, et al. Impact of tips preliver transplantation for the outcome post transplantation. Am J Transplant 2009; 9: 192-200.
112. Capling RK, Bastani B. The clinical course of patients with type 1 hepatorenal Ren Fail 2004; 26: 563-8.
113. Mitzner SR, Stange J, Klammt S, et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl 2000; 6: 277-86.
114. Bañares R, Nevens F, Larsen FS, et al. Extracorporeal liver support with the molecular adsorbent recirculating system (MARS) in patients with acute-on-chronic liver failure (AOCLF). The RELIEF trial [abstract 1184]. J Hepatol 2010; 52 (Suppl. 1): S459-60.
115. Wong F, Raina N, Richardson R. Molecular adsorbent recirculating system is ineffective in the management of type 1 hepatorenal syndrome in patients with cirrhosis with ascites who have failed vasoconstrictor treatment. Gut 2010; 59:381-6.
116. Rifai K, Kribben A, Gerken G, et al. Extracorporeal liver support by fractionated plasma separation and adsorption (Prometheus) in patients with acute-on-chronic liver failure (Helios study): a prospective randomized controlled multicenter study [abstract 6]. J Hepatol 2010; 52 (Suppl. 1): S3.
117. Kribben A, Gerken G, Haag S, et al. HELIOS Study Group. Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure. Gastroenterology 2012; 142: 782-9.
118. Gines P, Guevara M, Arroyo V, et al. Hepatorenal syndrome. Lancet 2003; 362: 1819-27.
119. Restuccia T, Ortega R, Guevara M, et al. Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome: a case-control study. J Hepatol 2004; 40: 140-6.
120. Marik PE, Wood K, Starzl TE. The course of type 1 hepato-renal syndrome post liver transplantation. Nephrol Dial Transplant 2006; 21: 478-82.
121. Piano S, Morando F, Fasolato S, et al. Continuous recurrence of type 1 hepatorenal syndrome and long-term treatment with terlipressin and albumin: a new exception to MELD score in the allocation system to liver transplantation? J Hepatol 2011; 55: 491-6.
122. Angeli P, Gines P. Hepatorenal syndrome, MELD score and liver transplantation: An evolving issue with relevant implications for clinical practice. J Hepatol 2012; 57: 1135-40.
123. Martín-Llahí M, Guevara M, Torre A, et al. Prognostic importance of the cause of renal failure in patients with cirrhosis. Gastroenterology 2011; 40: 488-96.
124. Charlton MR, Wall WJ, Ojo AO, et al. Report of the first international liver transplantation society expert panel consensus conference on renal insufficiency in liver transplantation. Liver Transpl 2009; 15: S1-S34.
125. Eason JD, Gonwa TA, Davis CL, et al. Proceedings of consensus conference on simultaneous liver kidney transplantation (SLK). Am J Transplant 2008; 8: 2243-51.